SS Innovations Reports Record Q1 2026 Revenue, Driven by Strong Growth in Surgical Robot Installations

SS Innovations International, Inc. (Nasdaq: SSII) announced unaudited financial results for the first quarter of 2026, reporting record quarterly revenue of $11.1 million, a 116.8% increase from $5.1 million in the same period last year. The company attributed the growth to robust demand for its SSi Mantra surgical robotic system, with installations rising 73.3% to 26 units in the quarter. Gross margin expanded significantly to 48.0% from 21.2%, and gross profit surged 390.0% to $5.3 million. Net loss narrowed to $3.6 million, or $(0.02) per diluted share, compared to a net loss of $5.7 million, or $(0.03) per share, in the first quarter of 2025.

As of March 31, 2026, the cumulative installed base of SSi Mantra systems reached 194 across eleven countries, and cumulative surgeries totaled 9,744, including 157 telesurgeries, 482 cardiac procedures, and 161 pediatric surgeries. The company reported no long-term debt and cash and cash equivalents of $16.0 million, excluding restricted cash. A private placement in March 2026 raised approximately $18.6 million in gross proceeds to support growth initiatives.

Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, commented, “Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency.” He highlighted regulatory approvals received in Sri Lanka and Kenya for multiple indications, and for telesurgery in Indonesia and the Philippines. Dr. Srivastava added, “We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year. Separately, we continue along the pathway towards a European Union CE marking certification, which we believe we can also obtain in 2026.”

The company’s focus on expanding its global footprint, particularly in underserved countries, and securing entry into the U.S. and EU markets underscores the strategic importance of these developments. The SSi Mantra system, with its modular design, 3D 4K visualization, and telesurgery capabilities, is positioned to democratize access to advanced robotic surgery. For more information, visit the company’s website at ssinnovations.com or follow updates on LinkedIn. The latest news and updates relating to $SSII are available in the company’s newsroom at https://tinyurl.com/ssiinewsroom.